A Cardiometabolic CRO Powered by Science, Built for Biotech
Looking for a Cardiometabolic CRO?
We support biotech sponsors through complex cardiovascular and metabolic trials — from first-in-human (FIH) to Phase IV — using scientifically grounded strategies. Our integrated approach helps streamline development timelines while generating robust, submission-ready data.
Driving Innovation in Cardiovascular and Metabolic Drug Development
Allucent delivers comprehensive support to biotech sponsors developing therapies for cardiovascular and metabolic conditions, including obesity and heart failure, and hypertension clinical trials. From early-phase design to global execution, we help bring first-in-class and best-in-class treatments to patients with speed, precision, and regulatory confidence.
End-to-End Cardiometabolic CRO Services
- Protocol design and site feasibility
- Regulatory strategy and agency engagement
- Clinical trial operations
- Patient recruitment and retention strategies
- Global site activation
- Data management & Biostatistics
- eCOA integration
- Imaging, biomarkers, composite scoring and lab support
- Ongoing Medical Monitoring and Pharmacovigilance
- Clinical pharmacology studies
- Dose optimization
Proven Success with Biotech Sponsors
- First-in-human trial for a novel GLP-1 agonist in obesity with Type 2 diabetes
- Global Phase IIb study for NASH with CV risk stratification
- CVOT study design and regulatory submission support for a lipid-lowering therapy
Partner with Our Cardiometabolic Experts
Whether you’re targeting early-phase validation or large-scale global trials, our cardiometabolic clinical trial team delivers scientific insight, operational agility, and regulatory clarity. Let’s work together to accelerate your program.
Therapeutic Focus Areas
Cardiovascular Diseases
- Heart Failure
- Hypertension
- Arrhythmias
- Pulmonary artery hypertension (PAH)
- Peripheral artery disease (PAD)
- Acute coronary syndromes (ACS)
Metabolic Disorders
- Type 2 diabetes and diabetic complications
- Obesity and metabolic syndrome
- Dyslipidemia and familial hypercholesterolemia
- MASH/MASLD
- Chronic kidney disease (CKD)
Cardio-Renal and Cardiometabolic Syndromes
- Atherosclerosis
- Uremic cardiomyopathy
Phase Expertise
- First-in-human (FIH) and proof-of-concept studies
- Seamless Phase I/II and adaptive trial designs
- Cardiovascular outcome trials (CVOT)
- Real-world evidence and post-marketing studies
Operational Strengths
- Experience with complex, comorbid patient populations
- Rapid global site start-up and enrollment
- Composite endpoint scoring and adjudication review
- Risk-based monitoring with real-time data access
- Strategic collaborations with key opinion leaders (KOLs)
Top Challenges in Cardiometabolic Drug Development – and How We Help
SPEED TO MARKET
In today’s fast-paced and competitive biotech landscape, speed to market is critical—especially in the cardiometabolic space where therapeutic innovation must keep pace with escalating patient needs and investor expectations. At Allucent we specialize in accelerating clinical development for complex cardiovascular disease and metabolic indications, navigating regulatory nuances and operational challenges with precision. Our expertise in managing studies involving high-risk and comorbid patient populations enables faster enrollment, streamlined trial execution, and data integrity without compromise—empowering biotech sponsors to bring life-changing treatments to market with confidence and urgency.
ENROLLING COMPLEX PATIENT POPULATIONS
Cardiometabolic trials and obesity trials often require patients with advanced disease or multiple comorbidities. We leverage disease-specific registries and global investigator networks to identify qualified sites and accelerate enrollment.
COMPLEX REGULATORY EXPECTATIONS
Global regulators demand robust evidence of efficacy and safety, particularly for cardiovascular risk. Our regulatory team guides strategy and dossier development, including protocol alignment with CVOT or FDA-mandated endpoints.
MANAGING OPERATIONAL AND DATA COMPLEXITY
These trials involve intensive monitoring, imaging, lab assessments, and long-term follow-up. We integrate biomarker data, imaging, and centralized safety adjudication within a unified data strategy. We train and qualify sites in imaging and other protocol procedures with close collaboration with core labs.
DEMONSTRATING LONG-TERM BENEFIT AND DIFFERENTIATION
Cardiometabolic therapies must show durable outcomes in diverse populations. We support adaptive trial designs, real-world evidence generation, and payer-relevant endpoints to position your asset competitively.
As a physician and scientist, I’ve witnessed the unique challenges biotech sponsors face in developing novel cardiometabolic therapies. At our CRO, our team combines scientific rigor with agile operations to deliver robust data and accelerate timelines—even in complex studies spanning FIH, MASH, and cardiovascular outcomes trials. We collaborate closely with global investigators and key opinion leaders to ensure successful enrollment and regulatory-ready results. If you need a CRO partner dedicated to innovation and your program’s success, our experienced team is ready to support you.
Jack Snyder, MD, JD, PhD
Senior Director, General Medicine
Cardiometabolic Experience
150+
Trials
2660+
Sites
17640+
Patients
